Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Michaël Cerezo(Université Paris-Sud), Caroline Robert(Institut Gustave Roussy), Delphine Allard, Julien Adam(Inserm), Nahum Sonenberg(McGill University), Séverine Le Roy(Université Paris-Saclay), Sabine Druillennec(Inserm), Shensi Shen(Sichuan University), Jean‐Yves Scoazec(Université Paris-Saclay), Alain Eychène(Université Paris-Sud), Émilie Routier(Université Paris-Saclay), Charlène Estrada(Centre National de la Recherche Scientifique), Alexander M.M. Eggermont(University Medical Center Utrecht), C. Libenciuc(Institut Gustave Roussy), Ramdane Guemiri(Université Paris-Sud), Hélène Malka-Mahieu(Université Paris-Sud), Laurent Désaubry(Centre National de la Recherche Scientifique), Stéphan Vagner(Institut Curie), Sandrine Agoussi(Inserm), Isabelle Girault(Inserm), Sylvain Martineau(Université Paris-Sud), Caroline Welsch(Université Paris-Sud)
Cited by 265
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Upstream and downstream of mTOR
|Genes & Development|2004|4.2k